WAY-213613 hydrochloride

For research use only. Not for therapeutic Use.

  • CAT Number: I046106
  • CAS Number: 2450268-84-3
  • Molecular Formula: C16H14BrClF2N2O4
  • Molecular Weight: 451.65
  • Purity: ≥95%
Inquiry Now

WAY-213613 (hydrochloride) is a potent and selective human EAAT2 inhibitor. WAY-213613 has potent EAAT2 inhibitory activity with an IC50 value of 85 nM. WAY-213613 can be used for the research of central nervous system[1].
WAY-213613 (hydrochloride) (0-100 μM) has inhibitory activity for human EAAT1, EAAT2 and EAAT3 subtype with IC50 values of 5004 nM, 85 nM and 3787 nM, respectively[1].??
WAY-213613 (3, 30, 300 nM) has the inhibitory effect on synaptosomal L-[3H] glutamate uptake with Ki values of 15 nM, 41 nM and 55 nM in the presence of 3, 30 and 300 nM, respectively[1].
WAY-213613 (0-100 μM) produces a concentration-dependent block of glutamate-induced currents in EAAT1-, EAAT2- or
EAAT3-injected oocytes, with IC50 values of 48, 0.13 and 4.0 μM, respectively[1].
WAY-213613 (0.5–50 μM) exhibits good selectivity over ionotropic receptors and EAAT2 and potent activity toward blocking NMDA-stimulated responses[1].


Catalog Number I046106
CAS Number 2450268-84-3
Synonyms

(2S)-2-amino-4-[4-(2-bromo-4,5-difluorophenoxy)anilino]-4-oxobutanoic acid;hydrochloride

Molecular Formula C16H14BrClF2N2O4
Purity ≥95%
InChI InChI=1S/C16H13BrF2N2O4.ClH/c17-10-5-11(18)12(19)6-14(10)25-9-3-1-8(2-4-9)21-15(22)7-13(20)16(23)24;/h1-6,13H,7,20H2,(H,21,22)(H,23,24);1H/t13-;/m0./s1
InChIKey IBCWXGJQAQXHPZ-ZOWNYOTGSA-N
SMILES C1=CC(=CC=C1NC(=O)CC(C(=O)O)N)OC2=CC(=C(C=C2Br)F)F.Cl
Reference

[1]. Dunlop J, et al. Characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT2. Mol Pharmacol. 2005 Oct;68(4):974-82. Epub 2005 Jul 13.
 [Content Brief]

[2]. Simmons DA, et al. A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer’s disease mouse models with mid- to late-stage disease progression. PLoS One. 2014 Aug 25;9(8):e102136.
 [Content Brief]

Request a Quote